These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The global cancer genetic testing market size was valued at USD 6.70 billion in 2024 and is projected to reach from USD 7.47 billion in 2025 to USD 17.98 billion by 2033, growing at a CAGR of 11.6% ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Can pollution cause it? What about inflammation? And how do tumors spread? Here’s what scientists are learning about this ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...